ender diagnostics, a Swiss company specializing in the development of rapid molecular biological tests, has launched ender MASS, its second CE-marked test to detect SARS-CoV-2, the virus which causes COVID-19. US FDA clearance is anticipated in September this year.
\nender MASS is highly specific, easy-to-use and fast \u2013 providing results from a simple nasopharyngeal swab in 30 minutes. It is designed to enable rapid diagnosis for critical settings including schools, manufacturing facilities, travel, hospitals and care homes, as well as enabling centralized laboratories to accelerate and increase throughput.
\nender diagnostics specializes in isothermal PCR-based test kits for laboratory and on-site diagnosis. It launched the ender LAB test in June 2020, which enables laboratories to directly detect SARS-CoV-2 on standard real-time PCR devices within 30 minutes, significantly faster than currently available PCR tests, which take several hours.
\nThe newly approved ender MASS offers further benefits by enabling detection in a simplified and accelerated process, considerably reducing the workload for medical professionals and laboratories. It is designed to enable on-site and pop-up labs to operate rapid testing in diverse settings, potentially including travel-related locations such as airports and cruise ships. The simplified workflows and analysis mean laboratories can process up to eight times as many tests compared to conventional PCR testing over the same period.
\nThe company is also moving ahead with development of a mobile point-of-care test for acute COVID-19 cases, called ender MOBILE. Launch in Europe is planned during Autumn this year. <\/p>\n
\nSupplier:<\/strong> [No title]
\nWebsite:<\/strong> https:\/\/enderdiagnostics.com<\/a><\/p>\n